San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, ARS Pharmaceuticals is raising $54,999,987.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Richard Lowenthal played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ARS Pharmaceuticals
Our mission at ARS Pharmaceuticals is to provide at-risk patients and their families better protection from severe allergic reactions. We are developing a product that patients and their caregivers can use without anxiety or hesitation, confident in the effectiveness of the both product and the ability to administer it. We are developing ARS-1, a novel intranasal epinephrine spray with a unique absorption technology that could be easy-to-use, convenient and more reliable for patients and loved ones at-risk of severe allergic reactions to food, medications and insect bites that could lead to life-threatening anaphylaxis.

To learn more about ARS Pharmaceuticals, visit http://ars-pharma.com/

Contact:
Richard Lowenthal, President and Chief Executive Officer
858-799-1840
https://www.linkedin.com/in/richard-lowenthal-82a4991/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved